Genscript Biotech Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Genscript Biotech wird ein jährliches Gewinn- und Umsatzwachstum von 112.7% bzw. 39.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 112.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.5% betragen.
Wichtige Informationen
112.7%
Wachstumsrate der Gewinne
112.5%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 44.8% |
| Wachstumsrate der Einnahmen | 39.9% |
| Zukünftige Eigenkapitalrendite | 9.5% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 23 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?
Feb 13
Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?
Jan 09Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,680 | 255 | -49 | 778 | 11 |
| 12/31/2025 | 1,809 | 42 | -200 | 97 | 12 |
| 12/31/2024 | 1,200 | -170 | -330 | -99 | 12 |
| 6/30/2024 | 1,010 | -177 | -276 | -20 | N/A |
| 3/31/2024 | 925 | -136 | -410 | -153 | N/A |
| 12/31/2023 | 840 | -95 | -543 | -287 | N/A |
| 9/30/2023 | 773 | -140 | -506 | -266 | N/A |
| 6/30/2023 | 707 | -185 | -523 | -245 | N/A |
| 3/31/2023 | 667 | -206 | -431 | -183 | N/A |
| 12/31/2022 | 626 | -227 | -339 | -120 | N/A |
| 9/30/2022 | 598 | -315 | -321 | -142 | N/A |
| 6/30/2022 | 570 | -403 | -304 | -163 | N/A |
| 3/31/2022 | 530 | -381 | -289 | -150 | N/A |
| 12/31/2021 | 490 | -359 | -274 | -137 | N/A |
| 9/30/2021 | 483 | -265 | -265 | -127 | N/A |
| 6/30/2021 | 454 | -183 | -256 | -118 | N/A |
| 3/31/2021 | 422 | -194 | -268 | -134 | N/A |
| 12/31/2020 | 391 | -205 | -279 | -151 | N/A |
| 9/30/2020 | 354 | -194 | -171 | -48 | N/A |
| 6/30/2020 | 318 | -183 | -64 | 54 | N/A |
| 3/31/2020 | 296 | -140 | -103 | 12 | N/A |
| 12/31/2019 | 273 | -97 | -142 | -30 | N/A |
| 9/30/2019 | 257 | -59 | -207 | -116 | N/A |
| 6/30/2019 | 241 | -22 | -272 | -202 | N/A |
| 3/31/2019 | 236 | 0 | -18 | 53 | N/A |
| 12/31/2018 | 231 | 21 | 236 | 308 | N/A |
| 9/30/2018 | 216 | 24 | 266 | 338 | N/A |
| 6/30/2018 | 201 | 27 | 297 | 369 | N/A |
| 3/31/2018 | 177 | 26 | N/A | 195 | N/A |
| 12/31/2017 | 153 | 26 | N/A | 21 | N/A |
| 9/30/2017 | 139 | 27 | N/A | 24 | N/A |
| 6/30/2017 | 125 | 28 | N/A | 27 | N/A |
| 3/31/2017 | 120 | 27 | N/A | 30 | N/A |
| 12/31/2016 | 115 | 26 | N/A | 33 | N/A |
| 9/30/2016 | 107 | 26 | N/A | 29 | N/A |
| 6/30/2016 | 99 | 25 | N/A | 25 | N/A |
| 3/31/2016 | 93 | 21 | N/A | 22 | N/A |
| 12/31/2015 | 87 | 18 | N/A | 20 | N/A |
| 9/30/2015 | 82 | 13 | N/A | 18 | N/A |
| 6/30/2015 | 78 | 8 | N/A | 16 | N/A |
| 3/31/2015 | 74 | 7 | N/A | 14 | N/A |
| 12/31/2014 | 70 | 6 | N/A | 12 | N/A |
| 12/31/2013 | 60 | 6 | N/A | 12 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1548 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).
Ertrag vs. Markt: 1548 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: 1548 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: 1548Die Einnahmen des Unternehmens (39.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.8% pro Jahr).
Hohe Wachstumseinnahmen: 1548Die Einnahmen des Unternehmens (39.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1548Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.5%).